Lassa fever

Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever

Retrieved on: 
Wednesday, March 20, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, DTRA, Conditional sentence, Inflammation, Viral, Marburg virus disease, Human, TLR7, Therapy, Lassa mammarenavirus, Lassa fever, Bleeding, Toll-like receptor 7, Vaccine

Primmune Therapeutics , a biotech company harnessing the power of the innate immune system, today announced that it was awarded a $22,480,552 contract by the Defense Threat Reduction Agency (DTRA) to develop PRTX007 as an oral broad spectrum antiviral TLR7 agonist for the treatment of Lassa fever.

Key Points: 
  • Primmune Therapeutics , a biotech company harnessing the power of the innate immune system, today announced that it was awarded a $22,480,552 contract by the Defense Threat Reduction Agency (DTRA) to develop PRTX007 as an oral broad spectrum antiviral TLR7 agonist for the treatment of Lassa fever.
  • The objective of the program is to evaluate the efficacy of PRTX007 in a series of animal models for Lassa fever and establish an effective treatment method of Lassa virus in humans.
  • “Primmune has demonstrated broad spectrum antiviral activity with PRTX007 and with related compounds from our discovery and development program,” said Charlie McDermott, President, Chief Executive Officer and Director of Primmune Therapeutics.
  • “PRTX007’s novel immunologic approach has the potential for combination use with direct acting anti-viral agents – enabling widely applicable utility in the treatment of Lassa fever and other hemorrhagic viruses.”

IMUNON’s VP of R&D to Present at the Vaccines Summit-2023

Retrieved on: 
Tuesday, November 14, 2023
Lung, Lassa fever, DNA, Immune system, Vaccination, Mouse, Research, CD4, Infection, Science, CD8, Primate, Vaccine, Cancer, SARS-CoV-2, Boston

LAWRENCEVILLE, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company focused on harnessing the power of the immune system against cancer and infectious diseases, announces that Jean Boyer, Ph.D., vice president of preclinical research and development, will highlight the Company’s vaccine development work in a presentation at the Vaccines Summit-2023 underway in Boston. Dr. Boyer will present “Robust Immunogenicity and Protection with PlaCCine: A Novel DNA Vaccine Delivered with a Functionalized Polymeric Delivery System” during the “New Vaccine Development” session this afternoon. The presentation may be viewed on the Company’s website in the Scientific Presentations section here.

Key Points: 
  • Dr. Boyer will present “Robust Immunogenicity and Protection with PlaCCine: A Novel DNA Vaccine Delivered with a Functionalized Polymeric Delivery System” during the “New Vaccine Development” session this afternoon.
  • The presentation may be viewed on the Company’s website in the Scientific Presentations section here .
  • “Importantly, PlaCCine DNA vaccines demonstrate stability over at least 12 months at 4°C and for one month at 25°C.
  • As such, PlaCCine vaccines could be easily deployed to help contain outbreaks such Lassa fever, EBOLA or Marburg that occur in resource-challenged parts of the world.

LTS receives grant of $1.2 Million to support the development of thermostable mRNA formulations for Microneedle Array Patches

Retrieved on: 
Wednesday, December 6, 2023
Lassa fever, Rabies, Risk, Map, Vaccination, Bill, Patient, Vaccine, Infection, Messenger, Melinda French Gates, LTS, MAP, Congress, Malaria, Tuberculosis, Pharmaceutical industry, Developing country

The grant will support new formulation methods for mRNA, such as dissolvable microneedle array patches (MAPs), to increase the thermostability of the overall product for its use in low- and middle-income countries (LMICs), especially in hard-to-reach conditions.

Key Points: 
  • The grant will support new formulation methods for mRNA, such as dissolvable microneedle array patches (MAPs), to increase the thermostability of the overall product for its use in low- and middle-income countries (LMICs), especially in hard-to-reach conditions.
  • mRNA technology is considered a potential game-changer for a range of infectious diseases, including tuberculosis, malaria, and Lassa fever, which disproportionately affect people in LMICs.
  • The need for frozen storage of the current generation of mRNA vaccines is due to the fragility of mRNA molecules.
  • "The LTS MAP team is excited to have support from the Gates Foundation for the development of a thermostable mRNA/LNP MAP", said Dr. Frank Theobald, Head of MAP Program at LTS.

LTS receives grant of $1.2 Million to support the development of thermostable mRNA formulations for Microneedle Array Patches

Retrieved on: 
Wednesday, December 6, 2023
Lassa fever, Rabies, Risk, Map, Vaccination, Bill, Patient, Vaccine, Infection, Messenger, Melinda French Gates, LTS, MAP, Congress, Malaria, Tuberculosis, Pharmaceutical industry, Developing country

The grant will support new formulation methods for mRNA, such as dissolvable microneedle array patches (MAPs), to increase the thermostability of the overall product for its use in low- and middle-income countries (LMICs), especially in hard-to-reach conditions.

Key Points: 
  • The grant will support new formulation methods for mRNA, such as dissolvable microneedle array patches (MAPs), to increase the thermostability of the overall product for its use in low- and middle-income countries (LMICs), especially in hard-to-reach conditions.
  • mRNA technology is considered a potential game-changer for a range of infectious diseases, including tuberculosis, malaria, and Lassa fever, which disproportionately affect people in LMICs.
  • The need for frozen storage of the current generation of mRNA vaccines is due to the fragility of mRNA molecules.
  • "The LTS MAP team is excited to have support from the Gates Foundation for the development of a thermostable mRNA/LNP MAP", said Dr. Frank Theobald, Head of MAP Program at LTS.

Gates Foundation Celebrates 20 Years of "Grand Challenges" With New Investments and a Call to Make R&D Breakthroughs Available More Quickly and Equitably

Retrieved on: 
Tuesday, October 10, 2023
Investment, Health, Infection, Agriculture, United, Vaccine, Tuberculosis, US, Government, AI, Grand Challenges, LLM Lettering, Equitable, Bill, Death, Grand Challenges Canada, R, Lassa fever, Artificial intelligence, Education, Bill & Melinda Gates Foundation, Sanitation, GC, Malaria, International development, Melinda French Gates, Drug discovery, Messenger, Women's health, Research, Global health, Pharmaceutical industry, Renewable energy, Tourism, Medical device, Wellcome, Developing country

SEATTLE and DAKAR, Senegal, Oct. 10, 2023 /PRNewswire/ -- A slate of new initiatives to support locally led innovation was announced today in Dakar by the Bill & Melinda Gates Foundation and its partners at the Grand Challenges Annual Meeting. The investments come with an urgent call for countries to step up funding to make the research and development (R&D) of health and development innovations easier and faster, and to make the next generation of scientific and technological breakthroughs relevant and accessible to all.

Key Points: 
  • In 2020, the annual funding gap for product development targeting poverty-related and neglected diseases was estimated at US$2.6 billion.
  • "But lifesaving innovations still take too long to reach those who need them and are not always designed with equity from the start.
  • "New health technologies have the potential to save millions of lives, but R&D funding is going in the wrong direction," said Gates.
  • Today, Gates announced that the foundation is investing US$30 million to support a new artificial intelligence (AI) platform in Africa.

Gates Foundation Celebrates 20 Years of "Grand Challenges" With New Investments and a Call to Make R&D Breakthroughs Available More Quickly and Equitably

Retrieved on: 
Tuesday, October 10, 2023
Investment, Health, Infection, Agriculture, United, Vaccine, Tuberculosis, US, Government, AI, Grand Challenges, LLM Lettering, Equitable, Bill, Death, Grand Challenges Canada, R, Lassa fever, Artificial intelligence, Education, Bill & Melinda Gates Foundation, Sanitation, GC, Malaria, International development, Melinda French Gates, Drug discovery, Messenger, Women's health, Research, Global health, Pharmaceutical industry, Renewable energy, Tourism, Medical device, Wellcome, Developing country

SEATTLE and DAKAR, Senegal, Oct. 10, 2023 /PRNewswire/ -- A slate of new initiatives to support locally led innovation was announced today in Dakar by the Bill & Melinda Gates Foundation and its partners at the Grand Challenges Annual Meeting. The investments come with an urgent call for countries to step up funding to make the research and development (R&D) of health and development innovations easier and faster, and to make the next generation of scientific and technological breakthroughs relevant and accessible to all.

Key Points: 
  • In 2020, the annual funding gap for product development targeting poverty-related and neglected diseases was estimated at US$2.6 billion.
  • "But lifesaving innovations still take too long to reach those who need them and are not always designed with equity from the start.
  • "New health technologies have the potential to save millions of lives, but R&D funding is going in the wrong direction," said Gates.
  • Today, Gates announced that the foundation is investing US$30 million to support a new artificial intelligence (AI) platform in Africa.

IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus

Retrieved on: 
Thursday, August 24, 2023
National Institute of Allergy and Infectious Diseases, CRADA, Research, Lassa mammarenavirus, Development, Death, Incidence, Cooperative research and development agreement, Developed country, Risk, Lassa fever, NIAID, Laboratory, Infection, World Health Organization, Vaccine, Virology

LAWRENCEVILLE, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate the immunogenicity and efficacy of two IMUNON DNA-based Lassa virus vaccine candidates. Under the three-year agreement, the NIAID will assess the efficacy of PlaCCine DNA constructs against Lassa virus in guinea pig and non-human primate disease models, including both prime and prime-boost vaccine strategies.

Key Points: 
  • Under the three-year agreement, the NIAID will assess the efficacy of PlaCCine DNA constructs against Lassa virus in guinea pig and non-human primate disease models, including both prime and prime-boost vaccine strategies.
  • Lassa virus is typically spread by rodents and can cause Lassa fever, a viral hemorrhagic-fever disease that is a significant and growing public health concern with approximately 5,000 deaths annually.
  • Nearly 60 million people throughout West Africa are estimated to be at risk of contracting Lassa fever.
  • Because of its lethality and increasing incidence, NIAID and the World Health Organization have categorized Lassa virus as a Category A Priority Pathogen.

iBio Forges Research Collaboration with the National Institutes of Health

Retrieved on: 
Monday, June 12, 2023
Chem, Vaccine, Interim, Viral disease, National Institute of Allergy and Infectious Diseases, Immunity, Intelligence, Viral, Bangladesh Technical Education Board, Protein, VRC, Risk, SAN, Lassa fever, Immune system, Epitope, DVM, Virus, NIH, Infection

BRYAN, Texas and SAN DIEGO, June 12, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced that the Company has entered into a research collaboration with the National Institute of Allergy and Infectious Diseases (“NIAID”), a component of the National Institutes of Health (“NIH”), to investigate the potential of iBio’s patented AI-driven epitope steering platform for the development of a vaccine for Lassa fever, a sometimes fatal viral disease endemic to parts of West Africa.1 There is currently no vaccine available to prevent Lassa fever.

Key Points: 
  • Based on the viral epitopes identified by researchers at NIAID’s Vaccine Research Center (“VRC”), iBio will work with the VRC to determine if using iBio’s platform to steer immunity toward these epitopes offers advantages over other vaccine development approaches.
  • Should the collaboration be successful, researchers at the VRC may assess promising candidates in both in vitro and in vivo studies, and potentially advance a lead candidate to a Phase 1 clinical trial.
  • “This collaboration with the NIH represents a potential new application for, and validation of our patented AI discovery platform,” said Martin Brenner, DVM, Ph.D., iBio’s Interim Chief Executive Officer and Chief Scientific Officer.
  • They encompass an amino acid sequence that folds into a distinct three-dimensional shape within the full-length viral protein.

Global Viral Hemorrhagic Fever Treatment Market to Surpass USD 2.20 Billion By 2031| Growth Market Reports

Retrieved on: 
Monday, June 12, 2023
Vaccine, Yellow fever, Human, Ebola, Completeness, Prevalence, Rift Valley fever, Infection, Fever, Hantavirus pulmonary syndrome, Key, Viral hemorrhagic fever, Hygiene, VHF, Government, Blood, HPS, Animal, Lymphocytic choriomeningitis, Lassa fever, Research, Study, Disease, Retail, Online shopping, Video game, RVSV-ZEBOV vaccine, Medication, Others, Growth, Ribavirin, Forecast

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.

Key Points: 
  • The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.
  • Moreover, it provides crucial strategies that are helping market players to expand their market share.
  • For Any Questions on This Report: https://growthmarketreports.com/enquiry-before-buying/3851
    On the basis of region, the global viral hemorrhagic fever treatment market is classified as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
  • North America is projected to dominate the global market because it has a well-established R&D laboratory.

Global Viral Hemorrhagic Fever Treatment Market to Surpass USD 2.20 Billion By 2031| Growth Market Reports

Retrieved on: 
Monday, June 12, 2023
Vaccine, Yellow fever, Human, Ebola, Completeness, Prevalence, Rift Valley fever, Infection, Fever, Hantavirus pulmonary syndrome, Key, Viral hemorrhagic fever, Hygiene, VHF, Government, Blood, HPS, Animal, Lymphocytic choriomeningitis, Lassa fever, Research, Study, Disease, Retail, Online shopping, Video game, RVSV-ZEBOV vaccine, Medication, Others, Growth, Ribavirin, Forecast

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.

Key Points: 
  • The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.
  • Moreover, it provides crucial strategies that are helping market players to expand their market share.
  • For Any Questions on This Report: https://growthmarketreports.com/enquiry-before-buying/3851
    On the basis of region, the global viral hemorrhagic fever treatment market is classified as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
  • North America is projected to dominate the global market because it has a well-established R&D laboratory.